Abstracts tagged "Perioperative management"

Abstract Number: 1892 • 2019 ACR/ARP Annual Meeting
Association Between Rheumatoid Arthritis Treatment and the Risk of Death or Readmission After Major Surgery
Michael George¹, Joshua Baker ², Kevin Winthrop ³, Lang Chen ⁴, Qufei Wu ², Fenglong Xie ⁵ and Jeffrey Curtis ⁴, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Oregon Health and Science University, Portland, OR, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham
Background/Purpose: The impact of immunosuppression on post-operative outcomes in rheumatoid arthritis (RA) has primarily been studied in patients undergoing joint replacement surgery. We aimed to…
Abstract Number: 1457 • 2017 ACR/ARHP Annual Meeting
Perioperative Management of Methotrexate and Tumor Necrosis Factor Inhibitor Combination Therapy in Rheumatoid Arthritis Patients
Hsin-Hsuan Juo^1,2 and Bernard Ng^1,3, ¹rheumatology, University of Washington, seattle, WA, ²rheumatology, VA Puget Sound Health Care System, seattle, WA, ³Rheumatology, VA Puget Sound Health Care System, seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) patients have a higher frequency of requiring surgical procedures and worse surgical outcome. However, literature regarding post-surgical infectious outcome associated with…
Abstract Number: 2755 • 2017 ACR/ARHP Annual Meeting
Comparative Risk of Biologic Therapies in Patients with Rheumatoid Arthritis Undergoing Elective Arthroplasty
Michael D. George¹, Joshua Baker², Kevin Winthrop³, E Alemao⁴, Lang Chen⁵, SE Connolly⁴, TA Simon⁴, Qufei Wu⁶, Fenglong Xie⁷, Shuo Yang⁷ and Jeffrey R. Curtis⁸, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Oregon Health Sciences University, Portland, OR, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Biostatistics and Analysis Center, University of Pennsylvania, Philadelphia, PA, ⁷Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic DMARDs have varying mechanisms of action and may be associated with different infection risks. The perioperative time period is a particularly high-risk time…
Abstract Number: 2786 • 2017 ACR/ARHP Annual Meeting
Timing of Abatacept Infusions before Elective Arthroplasty and the Risk of Post-Operative Infection
Michael D. George¹, Joshua Baker², Kevin Winthrop³, E Alemao⁴, Lang Chen⁵, SE Connolly⁴, TA Simon⁴, Qufei Wu⁶, Fenglong Xie⁷, Shuo Yang⁷ and Jeffrey R. Curtis⁸, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Oregon Health Sciences University, Portland, OR, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Biostatistics and Analysis Center, University of Pennsylvania, Philadelphia, PA, ⁷Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Current guidelines recommend holding biologic DMARDs before major surgery, despite limited data. Few studies have examined perioperative timing of individual biologic therapies. This study…
Abstract Number: 1520 • 2016 ACR/ARHP Annual Meeting
RA Flare after Total Hip and Total Knee Arthroplasty: Preliminary Outcomes at 1 Year
Susan M. Goodman¹, Susan J. Bartlett², Ryan Cummings³, Kathleen Andersen³, Edward F. DiCarlo⁴, Mark P. Figgie⁵, Laura T. Donlin⁶, Dana E. Orange⁷ and Vivian P. Bykerk⁸, ¹Medicine, Hospital for Special Surgery, New York, NY, ²Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ³Hospital for Special Surgery, New York, NY, ⁴Laboratory Medicine, Hospital for Special Surgery, New York, NY, ⁵Orthopaedics, Hospital for Special Surgery, New York, NY, ⁶Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Post-op flares are frequent for RA patients after total hip (THA) and total knee arthroplasty (TKA), when medications are discontinued to mitigate infection…
Abstract Number: 1792 • 2016 ACR/ARHP Annual Meeting
Cardiac Surgery in Systemic Lupus Erythematosus Patients: Clinical Characteristics and Outcomes
Lauro Quintanilla-González¹, Javier Tejeda-Maldonado², Jaime Galindo-Uribe³ and Andrea Hinojosa-Azaola⁴, ¹Immunology & Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Cardiology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: To study the clinical characteristics and outcomes of Systemic Lupus Erythematosus (SLE) patients that underwent cardiac surgery. Methods: Retrospective analysis of 30 SLE patients…
Abstract Number: 2001 • 2016 ACR/ARHP Annual Meeting
Perioperative Use of Synthetic Disease-Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor α Inhibitors Does Not Associate with Increased Rates of Post-Operative Infections
Hsin-Hsuan Juo^1,2, Anders Peck^3,4, Nancy Gove⁵ and Bernard Ng^1,2, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ²Rheumatology, VA Puget Sound Healthcare System, Seattle, WA, ³Medicine / Rheumatology, University of Washington, Seattle, WA, ⁴The Seattle Arthritis Clinic, Seattle, WA, ⁵Biostatistics, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: The aim of the study is to assess whether the risk of post-operative infectious complications in rheumatoid arthritis (RA) patients undergoing surgical procedures is…
Abstract Number: 2052 • 2016 ACR/ARHP Annual Meeting
Preoperative Timing of Infliximab and Risk of Post-Operative Infection in a Medicare Cohort
Michael D. George¹, Joshua F. Baker¹, Jesse Yenchih Hsu², Qufei Wu³, Fenglong Xie⁴, Lang Chen⁴, Huifeng Yun⁵ and Jeffrey Curtis⁶, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Biostatistics, University of Pennsylvania, Philadelphia, PA, ³Biostatistics and Analysis Center, University of Pennsylvania, Philadelphia, PA, ⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁶Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients taking biologic DMARDs often undergo elective surgery, but data to guide if and when to hold biologics before surgery is limited. This study…
Abstract Number: 2369 • 2014 ACR/ARHP Annual Meeting
Management of Perioperative Tumor Necrosis -á Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis
Susan M. Goodman¹, Indu Menon², Rie Smethurst³, Paul Christos⁴ and Vivian P. Bykerk¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, NY, NY, ³Education - Academic Training, Hospital for Special Surgery, NY, NY, ⁴Healthcare Policy and Research, Weill Cornell Medical College, NY, NY
Background/Purpose: Tumor Necrosis Factor α inhibitors (TNFi) are widely used in patients with RA (Rheumatoid Arthritis) undergoing orthopedic surgery, yet its optimal perioperative management is…
Abstract Number: 2370 • 2014 ACR/ARHP Annual Meeting
Management of Perioperative Tumor Necrosis Factor α Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis
Susan M. Goodman¹, Indu Menon², Rie Smethurst³, Paul Christos⁴ and Vivian P. Bykerk¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, NY, NY, ³Education - Academic Training, Hospital for Special Surgery, NY, NY, ⁴Healthcare Policy and Research, Weill Cornell Medical College, NY, NY
Background/Purpose: Tumor Necrosis Factor α inhibitors (TNFi) are widely used in patients with RA (Rheumatoid Arthritis) undergoing orthopedic surgery, yet its optimal perioperative management is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].